FDMT

9.66

2.55% 0.24

Handel nachbörslich: 9.66

4 D Molecular Therapeutics Inc (FDMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.42

Offen:

$9.72

24-Stunden-Volumen:

892.21K

Relative Volume:

1.15

Marktkapitalisierung:

$504.99M

Einnahmen:

$88.24M

Nettoeinkommen (Verlust:

$-160.90M

KGV:

-3.6259

EPS:

-2.6642

Netto-Cashflow:

$-129.35M

1W Leistung:

+9.34%

1M Leistung:

+15.48%

6M Leistung:

+11.16%

1J Leistung:

+136.19%

1-Tages-Spanne:

$9.45

$9.97

1-Wochen-Bereich:

$8.548

$9.97

52-Wochen-Spanne:

$3.68

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Firmenname

4 D Molecular Therapeutics Inc

Sektor

Healthcare (1104)

Branche

Biotechnology (617)

Telefon

(510) 505-2680

Adresse

5858 HORTON STREET #455, EMERYVILLE

Mitarbeiter

196

Twitter

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FDMT 4 D Molecular Therapeutics Inc	9.66	504.99M	88.24M	-160.90M	-129.35M	-2.6642
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-11-07	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2025-01-13	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Eingeleitet	Morgan Stanley	Underweight
2024-09-23	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Eingeleitet	Barclays	Overweight
2024-02-07	Fortgesetzt	Goldman	Buy
2023-10-26	Eingeleitet	RBC Capital Mkts	Outperform
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-18	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-07-05	Eingeleitet	Chardan Capital Markets	Buy
2023-01-30	Eingeleitet	BMO Capital Markets	Outperform
2022-11-18	Eingeleitet	H.C. Wainwright	Buy
2022-11-15	Hochstufung	Goldman	Neutral → Buy
2022-08-12	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Eingeleitet	Jefferies	Buy
2022-01-04	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	BofA Securities	Buy
2021-01-05	Eingeleitet	Evercore ISI	Outperform
2021-01-05	Eingeleitet	Goldman	Neutral

Alle ansehen

4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten

Jun 18, 2026

4D Molecular Therapeutics (FDMT) director granted 50,000 stock options with CIC vesting - Stock Titan

Jun 18, 2026

4D Molecular (NASDAQ: FDMT) grants director 50,000 stock options - Stock Titan

Jun 18, 2026

4D Molecular Therapeutics (FDMT) director receives 50,000-share stock option grant - Stock Titan

Jun 18, 2026

4D Molecular (NASDAQ: FDMT) director gets 50,000 stock options grant - Stock Titan

Jun 18, 2026

4D Molecular Therapeutics (FDMT) grants director John F. Milligan 75,000 options - Stock Titan

Jun 18, 2026

4D Molecular (FDMT) grants director 50,000 stock options at $9.42 - Stock Titan

Jun 18, 2026

Director at 4D Molecular Therapeutics (NASDAQ: FDMT) receives 50,000 options - Stock Titan

Jun 18, 2026

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times

Jun 18, 2026

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

Jun 18, 2026